NEW YORK, NY / ACCESSWIRE / August 18, 2017 / Shares of Wal-Mart saw a decline in yesterday's trading despite the fact that the company posted stellar growth in its online sales division in the second quarter. Same store sales also saw a jump for the period. Traders may be weary over the company's future with Amazon being a big rival. Mylan traded pretty flat on Thursday but finally settled with federal authorities the overcharging of its EpiPen in the Medicaid program.

RDI Initiates Coverage on:

Wal-Mart Stores, Inc.
https://ub.rdinvesting.com/news/?ticker=WMT

Mylan N.V.
https://ub.rdinvesting.com/news/?ticker=MYL

Wal-Mart Stores, Inc.'s shares closed down 1.58% yesterday on nearly double trading volume compared to usual. Despite the loss, it was a good day for the world's largest retailer. Walmart reported its second quarter earnings results and online sales were soaring. The company posted a big jump in its sales for the three month period. Sales at its Walmart.com, Jet.com, Modcloth and Moosejaw websites contributed to a 60% growth in online sales during the quarter. Sales at the company's U.S. stores open for at least a year also saw a jump of 1.8%. It was the 12th straight quarter of growth for Walmart in this category. Earnings per share for the period came to $1.08 per share, beating the Wall Street estimate by one penny. Looking ahead the company has forecast full year adjusted earnings of $4.30 to $4.40 per share while the Street is expecting $4.36 a share. Shares of the stock are up roughly 15% since the year started.

Access RDI's Wal-Mart Stores, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=WMT

Mylan N.V.'s shares closed up a modest 0.30% on Thursday with around 8.8 million shares traded. It was a day of closure for the company and many upset consumers. The company reached a deal with federal authorities to settle claims that it overcharged the Medicaid program by millions of dollars for its EpiPen products. The settlement amount? $465 million. This is the second settlement that Mylan has made since 2009 for the alleged overcharging of medicines to the government. It was Sanofi Aventis US LLC that blew the whistle on the company for the EpiPen overcharges and filed a lawsuit against Mylan under the False Claims Act. "Taxpayers rightly expect companies like Mylan that receive payments from taxpayer-funded programs to scrupulously follow the rules," Acting U.S. Attorney William Weinreb said in a statement.

Access RDI's Mylan N.V. Research Report at:
https://ub.rdinvesting.com/news/?ticker=MYL

Our Actionable Research on Wal-Mart Stores, Inc. (NYSE: WMT) and Mylan N.V. (NASDAQ: MYL) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com